Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AXL | P30530 | 11/20 | 0.88 |
| ▸ | MET | P08581 | 11/20 | 0.88 |
| ▸ | AURKB | Q96GD4 | 4/20 | 0.88 |
| ▸ | MERTK | Q12866 | 3/20 | 0.88 |
| ▸ | FLT1 | P17948 | 3/20 | 0.88 |
| ▸ | KDR | P35968 | 3/20 | 0.88 |
| ▸ | FLT3 | P36888 | 2/20 | 0.88 |
| ▸ | AURKA | O14965 | 1/20 | 0.88 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.88 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.88 |
| ▸ | ABL1 | P00519 | 1/20 | 0.88 |
| ▸ | EGFR | P00533 | 1/20 | 0.88 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.88 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.88 |
| ▸ | LCK | P06239 | 1/20 | 0.88 |
| ▸ | PGR | P06401 | 1/20 | 0.88 |
| ▸ | LYN | P07948 | 1/20 | 0.88 |
| ▸ | RET | P07949 | 1/20 | 0.88 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.88 |
| ▸ | HCK | P08631 | 1/20 | 0.88 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21688545 | 1.00 | AXL (0.88) | AXLMETAURKBMERTKFLT1 | |
| Cabozantinib SCHEMBL360795 | 0.94 | AXL (1.00) | AXLMETAURKBMERTKFLT1 | |
| Cabozantinib SCHEMBL29351408 | 0.94 | AXL (1.00) | AXLMETAURKBMERTKFLT1 | |
| Cabozantinib SCHEMBL29728791 | 0.94 | AXL (1.00) | AXLMETAURKBMERTKFLT1 | |
| Cabozantinib SCHEMBL18095042 | 0.93 | AXL (0.98) | AXLMETAURKBMERTKFLT1 | |
| Cabozantinib SCHEMBL18097906 | 0.91 | AXL (0.94) | AXLMETAURKBMERTKFLT1 | |
| SCHEMBL24414026 | 0.91 | MET (0.89) | AXLMETAURKBMERTKFLT1 | |
| Cabozantinib SCHEMBL18095040 | 0.90 | AXL (0.93) | AXLMETAURKBMERTKFLT1 | |
| SCHEMBL30692003 | 0.90 | AXL (0.93) | AXLMETAURKBMERTKFLT1 | |
| Cabozantinib SCHEMBL29195419 | 0.90 | AXL (0.91) | AXLMETAURKBMERTKFLT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230058971-A1 | EXTENDED RELEASE MICROPARTICLES AND SUSPENSIONS THEREOF FOR MEDICAL THERAPY | Graybug Vision, Inc. (US) | 2023-02-23 | — | — | US | disclosed |
| US-20230056284-A1 | EXTENDED RELEASE MICROPARTICLES AND SUSPENSIONS THEREOF FOR MEDICAL THERAPY | Graybug Vision, Inc. (US) | 2023-02-23 | — | — | US | disclosed |
| US-11548861-B2 | Drugs and compositions for the treatment of ocular disorders | Graybug Vision, Inc. (US) | 2023-01-10 | — | — | US | disclosed |
| US-11160870-B2 | Extended release microparticles and suspensions thereof for medical therapy | Graybug Vision, Inc. (US) | 2021-11-02 | — | — | US | disclosed |
| US-20200308162-A1 | DRUGS AND COMPOSITIONS FOR OCULAR DELIVERY | Graybug Vision, Inc. (US) | 2020-10-01 | — | — | US | disclosed |
| US-20200230246-A1 | EXTENDED RELEASE MICROPARTICLES AND SUSPENSIONS THEREOF FOR MEDICAL THERAPY | Graybug Vision, Inc. (US) | 2020-07-23 | — | — | US | disclosed |
| US-20200031783-A1 | DRUGS AND COMPOSITIONS FOR THE TREATMENT OF OCULAR DISORDERS | Graybug Vision, Inc. (US) | 2020-01-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200031783-A1 | DRUGS AND COMPOSITIONS FOR THE TREATMENT OF OCULAR DISORDERS | PDE6C, PDE6A, PDE6D | AXL 2544/4885MET 1312/4885AURKB 3194/4885 |
| US-11548861-B2 | Drugs and compositions for the treatment of ocular disorders | PDE6C, PDE6A, PDE6D | AXL 2544/4885MET 1312/4885AURKB 3194/4885 |
| US-20200308162-A1 | DRUGS AND COMPOSITIONS FOR OCULAR DELIVERY | AGER, PDE6B, PTGER1 | AXL 1278/4885MET 742/4885AURKB 1285/4885 |
| US-11160870-B2 | Extended release microparticles and suspensions thereof for medical therapy | CHMP4B, EXOSC9, EXOSC5 | AXL 129/4885MET 758/4885AURKB 794/4885 |
| US-20230058971-A1 | EXTENDED RELEASE MICROPARTICLES AND SUSPENSIONS THEREOF FOR MEDICAL THERAPY | CHMP4B, EXOSC9, EXOSC5 | AXL 129/4885MET 758/4885AURKB 794/4885 |
| US-20200230246-A1 | EXTENDED RELEASE MICROPARTICLES AND SUSPENSIONS THEREOF FOR MEDICAL THERAPY | CHMP4B, EXOSC9, EXOSC5 | AXL 129/4885MET 758/4885AURKB 794/4885 |
| US-20230056284-A1 | EXTENDED RELEASE MICROPARTICLES AND SUSPENSIONS THEREOF FOR MEDICAL THERAPY | CHMP4B, EXOSC9, EXOSC5 | AXL 129/4885MET 758/4885AURKB 794/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.